Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew F Alexis

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2023
Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin typeAndrew F Alexis, Jonathan I Silverberg, Zakiya P Rice, et al.
Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.
Dermatology and Therapy|July 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical TrialsAndrew F Alexis, Leon Kircik, Raj Chovatiya, et al.
American Journal of Clinical Dermatology|July 3, 2019
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsValerie D Callender, Andrew F Alexis, Linda F Stein Gold, et al.
Journal of Dermatological Science|January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyAndrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Journal of Drugs in Dermatology : JDD|December 4, 2024
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and AdolescentsLawrence F Eichenfield, Adelaide A Hebert, Julie C Harper, et al.
The Journal of Clinical and Aesthetic Dermatology|September 18, 2023
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of AcneJerry Tan, Zoe D Draelos, Melinda J Gooderham, et al.
The Journal of Dermatological Treatment|August 9, 2021
The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statementDaniel C Butler, Eric Simpson, Emma Guttman-Yassky, et al.
Dermatology and Therapy|October 2, 2024
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe PsoriasisAndrew F Alexis, Melinda Gooderham, Shawn G Kwatra, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 18, 2018
Atopic dermatitis in African American patients is TRiana D Sanyal, Ana B Pavel, Jacob Glickman, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2023
Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin typeAndrew F Alexis, Jonathan I Silverberg, Zakiya P Rice, et al.
Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.
Dermatology and Therapy|July 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical TrialsAndrew F Alexis, Leon Kircik, Raj Chovatiya, et al.
American Journal of Clinical Dermatology|July 3, 2019
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsValerie D Callender, Andrew F Alexis, Linda F Stein Gold, et al.
Journal of Dermatological Science|January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyAndrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Journal of Drugs in Dermatology : JDD|December 4, 2024
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and AdolescentsLawrence F Eichenfield, Adelaide A Hebert, Julie C Harper, et al.
The Journal of Clinical and Aesthetic Dermatology|September 18, 2023
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of AcneJerry Tan, Zoe D Draelos, Melinda J Gooderham, et al.
The Journal of Dermatological Treatment|August 9, 2021
The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statementDaniel C Butler, Eric Simpson, Emma Guttman-Yassky, et al.
Dermatology and Therapy|October 2, 2024
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe PsoriasisAndrew F Alexis, Melinda Gooderham, Shawn G Kwatra, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 18, 2018
Atopic dermatitis in African American patients is TRiana D Sanyal, Ana B Pavel, Jacob Glickman, et al.
Pageof 12